Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Biohaven Pharmaceutical Holding Company Ltd. BHVN

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NYSE:BHVN)

Fundamentals Snapshot (NYSE:BHVN)

Current News (NYSE:BHVN)

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, VIVO, HNGR, CMAX

PR Newswire 4 days ago

Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments

PR Newswire August 5, 2022

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates COWN, SWIR, BHVN, GLTA

PR Newswire August 3, 2022

American Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migraine and Mental Health Significantly Impact Each Other

PR Newswire July 28, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HMTV, BHVN, DRE, PLD

PR Newswire July 26, 2022

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, GRRB, SIMO, MN

PR Newswire July 13, 2022

Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)

PR Newswire July 7, 2022

Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven's Troriluzole and Vigeo'S VT1021 in GBM AGILE Trial

Business Wire July 6, 2022

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, MANT, PCSB, NLSN

PR Newswire July 6, 2022

Opinion & Analysis (NYSE:BHVN)

No current opinion is available.

Bullboard Posts (NYSE:BHVN)